Serum cytokines and bioumoral immunological characterization of psoriatic patients in long term etanercept treatment

International Journal of Immunopathology and Pharmacology

Volumn 21, Issue 3, 2008, Pages 643-649

  Cordiali Fei, P ^a   Ardigo M ^a   Mastroianni, A ^a   Giuliani, A ^a   D'Agosto, G ^a   Bordignon, V ^a   Trento, E ^a   Vento, A ^a   Berardesca, Enzo ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Cytokines; Etanercept; II 1; II 12; INF gamma; Long term treatment; Psoriasis; TNF alpha

Indexed keywords

ANTINUCLEAR ANTIBODY; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DNA ANTIBODY; ETANERCEPT; GAMMA INTERFERON; HISTONE ANTIBODY; IMMUNOGLOBULIN E; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY TITER; ARTHRITIS; ARTICLE; CD4 CD8 RATIO; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIASIS SEVERITY INDEX; TREATMENT DURATION;

EID: 53749101805     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200802100318     Document Type: Article

References (24)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.
2. Dermatol Clin 1996; 14:485-96. 2.Alenius GM, Stenberg B, Stenlund H, Lundblad M, Dahlqvist SR. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002; 29:2577-82.
3. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999; 38:241-251.
4. Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 2004; 22:449-459.
5. Bonifati C, Carducci M, Cordial Fei P et al. Correlated increases of tumor necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease activity. Clin Exp Dermatol 1994; 19:383-387.
6. Tan JK, Aphale A, Malavita R, Sun Y, Gottlieb AB. Mechanisms of action of ctanercept in psoriasis. J Invest Dermatol Symp Proc 2007; 12(l):38-45.
7. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000; 356:385-390.
8. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB & "Etanercept Psoriasis Study Group". Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349(21):2014-22.
9. Tyring S, Gottlieb A, Papp K,et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367(9504): 6-7.
10. Baker BS, Powles AV, Valdimarsson H, Fry L. An altered response by psoriatic keratinocytes to gamma interferon. Scand J Immunol 1988; 28(6):735-40.
11. Szabo SK, Hammerberg C, Yoshida Y, et al. Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol 1998; 111:1072-8.
12. Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993; 14:69-74.
13. Partsch G, Wagner E, Leeb BF et al. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis 1998; 57:691-3.
14. Partsch G, Steiner G, Leeb BF et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24:518-23.
15. Spadaro A, Taccari E, Riccieri V et al. Interleukin-6 and solubile interieukin-2 receptor in psoriatic arthritis: correlations with clinical and laboratory parameters. Clin Exp Rheumatol 1996; 14:413-16.
16. Carducci M, Mussi A, Bonifati C et al. sICAM-1, sIL-2R and beta 2-microglobulin serum levels in patients affected with psoriasis: relationship with disease severity. Arch Dermatol Res 1994; 286:420-2.
17. Kang S, Yi S, Griffiths CE et al. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998; 138:77-83.
18. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135(l):1-8.
19. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis. Arthritis Rheum 2004; 50:2264-2272.
20. Gratch N, Weinberg JM, Alexis AE Etanercept: a tumor necrosis factor inhibitor for psoriasis and psoriatic arthritis. Expert Rev Dermatol 2006; 1(4): 527-534.
21. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304-1312.
22. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha-induced systemic lupus; syndrome. Clin Rheumatol 2003; 22:56-61.
23. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359:579-580.
24. Mastroianni A, Minutilli E, Mussi A, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 2005; 153(3):531-536.